KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Operating Leases for 8 consecutive years, with $218.0 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Leases fell 5.23% year-over-year to $218.0 million; the TTM value through Mar 2026 reached $218.0 million, down 5.23%, while the annual FY2025 figure was $225.1 million, 1.94% down from the prior year.
  • Operating Leases hit $218.0 million in Q1 2026 for Alnylam Pharmaceuticals, down from $225.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $277.4 million in Q1 2022 and bottomed at $218.0 million in Q1 2026.
  • Average Operating Leases over 5 years is $243.8 million, with a median of $239.4 million recorded in 2024.
  • Year-over-year, Operating Leases dropped 8.32% in 2024 and then fell 1.94% in 2025.
  • Alnylam Pharmaceuticals' Operating Leases stood at $261.3 million in 2022, then decreased by 6.98% to $243.1 million in 2023, then fell by 5.58% to $229.5 million in 2024, then decreased by 1.94% to $225.1 million in 2025, then dropped by 3.14% to $218.0 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $218.0 million, $225.1 million, and $223.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.